* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:38:42 ON 26 AUG 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:38:49 ON 26 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file

h eb c g cg b cg eb

provided by InfoChem.

STRUCTURE FILE UPDATES: 25 AUG 2004 HIGHEST RN 732955-11-2
DICTIONARY FILE UPDATES: 25 AUG 2004 HIGHEST RN 732955-11-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

=> s l1
SAMPLE SEARCH INITIATED 15:50:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7718 TO ITERATE

13.0% PROCESSED 1000 ITERATIONS 8 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 149095 TO 159625
PROJECTED ANSWERS: 763 TO 1705

L2 8 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 15:50:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 153893 TO ITERATE

100.0% PROCESSED 153893 ITERATIONS 813 ANSWERS
SEARCH TIME: 00.00.05

L3 813 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 162.98 163.19

FILE 'HCAPLUS' ENTERED AT 15:50:21 ON 26 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

h eb c g cg b cg eb

FILE COVERS 1907 - 26 Aug 2004 VOL 141 ISS 9
FILE LAST UPDATED: 25 Aug 2004 (20040825/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 28 L3

=> s l4 and lu, z?/au
5751 LU, Z?/AU
L5 3 L4 AND LU, Z?/AU

=> d l5, ibib abs fhitstr, 1-3

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | CAPLUS References

ACCESSION NUMBER: 2003:511307 HCAPLUS
DOCUMENT NUMBER: 139:85368
TITLE: Preparation of barbituric acids as inhibitors of TNF-α converting enzyme (TACE), aggrecanase and/or matrix metalloproteinases
INVENTOR(S): Duan, Jingwu; Jiang, Bin; Chen, Lihua; **Lu, Zhonghui**; Barbosa, Joseph; Pitts, William
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 267 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053941	A2	20030703	WO 2002-US40458	20021217
WO 2003053941	A3	20030814		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

h eb c g cg b cg eb

US 2003229084 A1 20031211 US 2002-321144 20021217
PRIORITY APPLN. INFO.: US 2001-342658P P 20011220
OTHER SOURCE(S): MARPAT 139:85368
GI



I

AB The present application describes novel barbituric acid derivs. (shown as I; variables defined below; e.g. 5-methyl-5-[3-[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]-3-oxopropyl]-2,4,6(1H,3H,5H)-pyrimidinetrione) or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as TNF-α converting enzyme (TACE), aggrecanase and matrix metalloproteinases (MMP) inhibitors. Although the methods of prepn. are not claimed, 60 example prepns. are included. Some examples of I (specific compds. not stated) inhibit matrix metalloproteinases with Ki ≤10 μM. For I: A is C(O), C(S) or CH2; B is O or S; L is O or S; W = (CRaRa1)m, C2-3 alkenylene, and C2-3 alkynylene; U = C(O), CRa(OH), C(O)O, OC(O), C(O)NRa1, NRa1C(O), OC(O)O, OC(O)NRa1, NRa1C(O)O, and NRa1C(O)NRa1; X is absent or C1-3 alkylene, C2-3 alkenylene, and C2-3 alkynylene; Y is absent or O, NRa1, S(O)p, and C(O); Z = C3-13 carbocycle substituted with 0-5 Rb, and a 5-14 membered heterocycle comprising C atoms and 1-4 heteroatoms N, O, and S(O)p, and substituted with 0-5 Rb; Ua is absent or O, NRa1, C(O), CRa(OH), C(O)O, OC(O), C(O)NRa1, NRa1C(O), OC(O)O, OC(O)NRa1, NRa1C(O)O, NRa1C(O)NRa1, S(O)p, S(O)pNRa1, NRa1S(O)p, and NRa1SO2NRa1; Xa is absent or C1-10-alkylene, C2-10 alkenylene, and C2-10 alkynylene; Ya is absent or O, NRa1, S(O)p, and C(O); Za = C3-13 carbocycle substituted with 0-5 Rc and a 5-14 membered heterocycle comprising C atoms and 1-4 heteroatoms N, O, and S(O)p, and substituted with 0-5 Rc. R1 = CHF2, CH2F, CF3, C1-6 alkylene-Q (Q = H, CF3, etc.), etc.; R2 = Q1 (Q1 = H, carbocyclyl, heterocyclyl), C1-6 alkylene-Q1, etc.; R3 = Q, C1-6 alkylene-Q, etc.; R4, R5 = H, C1-6 alkyl, etc.; addnl. details including provisos are given in the claims.

IT **554451-88-6**, 3-[[4-[(2-Methylquinolin-4-yl)methoxy]benzoyl]amino]piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of barbituric acids as inhibitors of TNF-α converting enzyme, aggrecanase and/or matrix metalloproteinases)

RN 554451-88-6 HCAPLUS

CN 1,4-Piperidinedicarboxylic acid, 3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 1-(1,1-dimethylethyl) 4-methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L5 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | More References

ACCESSION NUMBER: 2003:242278 HCAPLUS
DOCUMENT NUMBER: 138:271682
TITLE: Preparation of cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme for treatment of inflammatory disorders
INVENTOR(S): Ott, Gregory; Chen, Xiao-Tao; Duan, Jingwu; **Lu, Zhonghui**
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 344 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024899	A2	20030327	WO 2002-US29685	20020916
WO 2003024899	A3	20031127		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,

h eb c g cg b cg eb

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003139388	A1	20030724	US 2002-244626	20020916
US 6740649	B2	20040525		
EP 1427408	A2	20040616	EP 2002-775865	20020916

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.: US 2001-322630P P 20010917
WO 2002-US29685 W 20020916

OTHER SOURCE(S): MARPAT 138:271682

GI



I



II

AB Title compds. I [wherein ring B = (un)substituted 4-7 membered (hetero)cyclic ring contg. 0-2 O, N, NR1, or SOp atoms and 0-3 carbonyl groups; R1 and R2 = independently Q, alk(en/yn)ylene-Q, or (un)substituted alkylene-Q interrupted by O, NRa, CO, CO2, CONRa, NRaCO, NRaCO2, NRaCONRa, SOp, NRaSO2, or SO2NRa; or R1 = (un)substituted alkylene-Q interrupted by OCO, OCO2, or OCONRa; Q = H or (un)substituted (hetero)cyclyl; R3 = Q1, Cl, F, alk(en/yn)ylene-Q1, or (un)substituted alkylene-Q1 interrupted by O, NR1, NRaCO, CONRa, CO, CO2, SOp, or SO2NRa; Q1 = H or (un)substituted Ph, naphthyl, or heterocyclyl; Za = (un)substituted benzimidazolyl, indolyl, imidazopyridinyl, pyrazolylpyridinyl, benzofuranyl, benzothiazinyl, quinolinyl, etc.; Ra = independently H, alkyl, Ph, or benzyl; p = 0-2; or stereoisomers or pharmaceutically acceptable salts thereof] were prepd. as inhibitors of matrix metalloproteinases (MMP), TNF-a converting enzyme (TACE), aggrecanase, or a combination thereof. For example, reaction of benzyl Me maleate with paraformaldehyde and glycine gave benzyl Me (cis)-3,4-pyrrolidinedicarboxlyate (100%). BOC-protection (64%), debenzylation (96%), resoln. of the (3S,4S)-isomer with (S)-α-methylbenzylamine, conversion to the carbamate with DPPA and PhCH2OH (76%), and Pd catalyzed hydrogenation (100%) provided Me (3S,4S)-4-amino-1-(tert-butoxycarbonyl)-3-pyrrolidinecarboxylate. Coupling of the amine with 4-[(2-methylthio-1H-benzimidazol-1-yl)methyl]benzoic acid (prepn. given) afforded the amide (99%), which was treated with NH2OH•HCl/MeONa to give the hydroxamic acid (3S,4S)-II (33%). A no. of the compds. of the invention inhibited MMP-1, 2, 3, 7, 8, 9, 10, 12, 13, 14, 15, and/or 16 with Ki values of ≤ 10 μM. Thus, I are useful for the treatment of a wide variety of inflammatory disorders (no data).

h eb c g cg b cg eb

IT **362489-81-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of cyclic hydroxamic acids as MMP and/or TACE inhibitors for treatment of inflammatory disorders)
RN 362489-81-4 HCAPLUS
CN 1,4-Piperidinedicarboxylic acid, 3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 1-(1,1-dimethylethyl) 4-ethyl ester, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L5 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER:	2001:713294 HCAPLUS
DOCUMENT NUMBER:	135:257169
TITLE:	Preparation of cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
INVENTOR(S):	Duan, Jingwu; Ott, Gregory; Chen, Linhua; **Lu, Zhonghui**; Maduskuie, Thomas P., Jr.; Voss, Matthew E.; Xue, Chu-Biao
PATENT ASSIGNEE(S):	Dupont Pharmaceuticals Company, USA
SOURCE:	PCT Int. Appl., 298 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

h eb c g cg b cg eb

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070673	A2	20010927	WO 2001-US8334	20010315
WO 2001070673	A3	20020314		
W: AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, HU, IN, JP, KR, LT, LU, LV, MX, NZ, PL, PT, RO, SE, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1263755	A2	20021211	EP 2001-924170	20010315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
BR 2001009467	A	20030603	BR 2001-9467	20010315
JP 2003528072	T2	20030924	JP 2001-568885	20010315
EE 200200529	A	20040216	EE 2002-529	20010315
US 2002016336	A1	20020207	US 2001-811233	20010316
US 6743807	B2	20040601		
US 2004162426	A1	20040819	US 2004-779539	20040213
PRIORITY APPLN. INFO.:			US 2000-190182P	P 20000317
			US 2000-233373P	P 20000918
			US 2000-255539P	P 20001214
			WO 2001-US8334	W 20010315
			US 2001-811233	A3 20010316

OTHER SOURCE(S): MARPAT 135:257169

AB Novel cyclic β-amino acid derivs. A-CRR2aCRR2bNR1CO-Z-Ua-Xa-Ya-Za [A = CO2H, CH2CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl, Ph, benzyl), P(O)(OH)2, etc.; CRCR is a substituted 3-13 membered nonarom. carbocyclic or heterocyclic ring; Z is absent or substituted C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRa1 (Ra1 = H, alkyl), CO, CO2, O2C, CONRa1, S(O)p (p = 0-2), etc.; Xa is absent or C1-10 alkylene, C2-10 alkenylene or alkynylene; Ya is absent or O, NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, C1-4 alkyl, Ph, benzyl; R2a is H, C1-6 alkyl, ORa, NRaRa1 or S(O)pRa; R2b is H, C1-6 alkyl (with provisos)] or pharmaceutically acceptable salts were prepd. as metalloprotease and TNF-α inhibitors. Thus, (3S,4S)-N-hydroxy-1-isopropyl-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-3-pyrrolidinecarboxamide was prepd. by a multistep procedure starting with condensation of benzyl Me maleate, glycine, and paraformaldehyde to form 3,4-pyrroledicarboxylate diester and involving amidation of 4-[(2-methyl-4-quinolinyl)methoxy]benzoic acid.

IT **362485-48-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of cyclic β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)

RN 362485-48-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 1,1-dimethylethyl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

h eb c g cg b cg eb

PAGE 1-A



PAGE 2-A




```
=> d his

     (FILE 'HOME' ENTERED AT 15:38:42 ON 26 AUG 2004)

     FILE 'REGISTRY' ENTERED AT 15:38:49 ON 26 AUG 2004
L1                STRUCTURE UPLOADED
L2              8 S L1
L3            813 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 15:50:21 ON 26 AUG 2004
L4             28 S L3
L5              3 S L4 AND LU, Z?/AU

=> s l4 not l5
L6            25 L4 NOT L5

=> s l6 and maduskuie, t?/au
              33 MADUSKUIE, T?/AU
L7             4 L6 AND MADUSKUIE, T?/AU

=> d l7, ibib abs fhitstr, 1-4

L7   ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

Full Text | Citing References

```
ACCESSION NUMBER:         2004:310829  HCAPLUS
```

h eb c g cg b cg eb

DOCUMENT NUMBER: 140:303552
TITLE: Preparation of β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
INVENTOR(S): Duan, Jingwu; King, Bryan W.; Decicco, Carl; **Maduskuie, Thomas P.**; Voss, Mathew E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 150 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004072802	A1	20040415	US 2002-267207	20021009
PRIORITY APPLN. INFO.:			US 2002-267207	20021009

OTHER SOURCE(S): MARPAT 140:303552

AB Novel β-amino acid derivs. A-CR3R4aCR2R4NR1CO-X-Z-Ua-Xa-Ya-Za [A = CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl), P(O)(OH)2, etc.; X, Xa is absent or alkylene, alkenylene or alkynylene; Z is absent or substituted C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRa1 [Ra1 = H, (un)substituted alkyl, alkenyl or alkynyl; Ra and Ra1 may form a ring], CO, CO2, O2C, CONRa1, S(O)p (p = 0-2), etc.; Ya is absent or O, NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, alkyl, Ph, benzyl; R2 is Q (Q is H, substituted carbocycle or heterocycle), alkylene-Q, (CRaRa1)r1O(CRaRa1)r-Q (r, r1 = 0-4), (CRaRa1)r1NRa(CRaRa1)r-Q, etc.; R3 = Q1 (Q1 is any group given for Q), alkylene-Q1, (CRaRa1)r1O(CRaRa1)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, etc.; R4, R4a = H, substituted alkyl, alkenyl or alkynyl; alternatively R1 and R2, R1 and R3, R3 and R4a may form rings (with provisos)] or a stereoisomer or pharmaceutically acceptable salt were prepd. as metalloprotease and TNF-α inhibitors. Thus, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-3-azetidinecarboxamide was prepd. by a multistep procedure involving reactions of Me 4-hydroxyphenylacetate, 2-methyl-4-quinolinylmethanol, and 3-azetidinecarboxylic acid Me ester.

IT **362701-28-8P**
RL: BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)

RN 362701-28-8 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, (3R)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362701-27-7
CMF C25 H28 N4 O4

Absolute stereochemistry.

h eb c g cg b cg eb



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L7 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:444499 HCAPLUS
DOCUMENT NUMBER: 137:33207
TITLE: Preparation of novel N-substituted-γ,γ-trisubstituted lactam derivatives as matrix metalloproteinase inhibitors
INVENTOR(S): Duan, Jingwu; DeCicco, Carl P.; Wasserman, Zelda R.; **Maduskuie, Thomas P., Jr.**
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 119 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6403632	B1	20020611	US 2000-516709	20000301
US 2003134827	A1	20030717	US 2002-96619	20020312
US 6610731	B2	20030826		

PRIORITY APPLN. INFO.:

US 1997-62418P	P	19971003
US 1998-165747	A3	19981002
US 2000-516709	A3	20000301

OTHER SOURCE(S): MARPAT 137:33207
GI

h eb c g cg b cg eb



I



II

AB Title compds. [I; A is selected from COOH, CH2COOH, CONHOH, SH, CH2SH, PO(OH)2, etc.; ring B is a 4-8 membered cyclic amide contg. 0-3 heteroatoms from O, N, and S, etc.; R1 is phenylmethoxyphenyl, phenoxyphenyl, etc.; R2 is H, CH3, Et, i-Pr, etc.; R1-R2 combine to form heterocyclic; R3 is H, alkylene, heterocyclic, etc.; R4 is H, alkylene, etc.; R3-R4 combine to form heterocyclic], stereoisomer, and pharmaceutically acceptable salt thereof are prepd. as useful metalloprotease inhibitors. For instance, 4-benzyloxyphenyl acetate was sequentially alkylated (THF, NaHMDS) with MeI and allyl bromide to afford the α,α-bis(alkylated) deriv. which was converted to the aldehyde (CH2Cl2, O3) and was subsequently reacted with D-alanine Me ester hydrochloride and Zn° in HOAc to yield the lactam ester. This intermediate was treated with hydroxylamine to give hydroxamic acid II.

IT **223403-20-1P**, 1-Pyrrolidineacetamide, 3-[4-[(2,6-dichloro-4-pyridinyl)methoxy]phenyl]-N-hydroxy-α-methyl-2-oxo-3-[[(4-pyridinylamino)carbonyl]amino]-, (αR)-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(N-γ,γ-trisubstituted lactam derivs. as MMP-3/aggrecanase inhibitors)

RN 223403-20-1 HCAPLUS

CN 1-Pyrrolidineacetamide, 3-[4-[(2,6-dichloro-4-pyridinyl)methoxy]phenyl]-N-hydroxy-α-methyl-2-oxo-3-[[(4-pyridinylamino)carbonyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

h eb c g cg b cg eb



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:713343 HCAPLUS
DOCUMENT NUMBER: 135:272894
TITLE: Preparation of β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
INVENTOR(S): Duan, Jingwu; King, Bryan W.; Decicco, Carl; **Maduskuie, Thomas P., Jr.**; Voss, Matthew E.
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 483 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070734	A2	20010927	WO 2001-US8336	20010315
WO 2001070734	A3	20020314		
W: AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, IL, IN, JP, KR, LT, LU, LV, NZ, PL, PT, RO, SE, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001050850	A5	20011003	AU 2001-50850	20010315
EP 1263756	A2	20021211	EP 2001-924171	20010315
EP 1263756	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
BR 2001009469	A	20030429	BR 2001-9469	20010315
JP 2003528097	T2	20030924	JP 2001-568935	20010315
AT 260272	E	20040315	AT 2001-924171	20010315
US 2002013341	A1	20020131	US 2001-811116	20010316
US 6495565	B2	20021217		
PRIORITY APPLN. INFO.:			US 2000-190183P	P 20000317
			US 2000-235467P	P 20000926
			US 2000-252062P	P 20001120
			WO 2001-US8336	W 20010315

OTHER SOURCE(S): MARPAT 135:272894

AB Novel β-amino acid derivs. A-CR3R4aCR2R4NR1CO-X-Z-Ua-Xa-Ya-Za [A = CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl), P(O)(OH)2, etc.; X, Xa is absent or alkylene, alkenylene or alkynylene; Z is absent or substituted

h eb c g cg b cg eb

C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRa1 [Ra1 = H, (un)substituted alkyl, alkenyl or alkynyl; Ra and Ra1 may form a ring], CO, CO2, O2C, CONRa1, S(O)p (p = 0-2), etc.; Ya is absent or O, NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, alkyl, Ph, benzyl; R2 is Q (Q is H, substituted carbocycle or heterocycle), alkylene-Q, (CRaRa1)r1O(CRaRa1)r-Q (r, r1 = 0-4), (CRaRa1)r1NRa(CRaRa1)r-Q, etc.; R3 = Q1 (Q1 is any group given for Q), alkylene-Q1, (CRaRa1)r1O(CRaRa1)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, etc.; R4, R4a = H, substituted alkyl, alkenyl or alkynyl; alternatively R1 and R2, R1 and R3, R3 and R4a may form rings (with provisos)] or a stereoisomer or pharmaceutically acceptable salt were prepd. as metalloprotease and TNF-α inhibitors. Thus, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-3-azetidinecarboxamide was prepd. by a multistep procedure involving reactions of Me 4-hydroxyphenylacetate, 2-methyl-4-quinolinylmethanol, and 3-azetidinecarboxylic acid Me ester.

IT **362701-28-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)

RN 362701-28-8 HCAPLUS

CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, (3R)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362701-27-7
CMF C25 H28 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

h eb c g cg b cg eb



L7 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:244635 HCAPLUS
DOCUMENT NUMBER: 130:296611
TITLE: Preparation of novel lactam as metalloprotease inhibitors
INVENTOR(S): Duan, Jinguw; Decicco, Carl P.; Wasserman, Zelda R.; **Maduskuie, Thomas P., Jr.**
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 333 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9918074	A1	19990415	WO 1998-US21037		19981002
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
ZA 9808967	A	20000403	ZA 1998-8967		19981001
CA 2305679	AA	19990415	CA 1998-2305679		19981002
AU 9896866	A1	19990427	AU 1998-96866		19981002
AU 747239	B2	20020509			
US 6057336	A	20000502	US 1998-165747		19981002
EP 1027332	A1	20000816	EP 1998-950954		19981002
EP 1027332	B1	20040526			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO					
BR 9815398	A	20001031	BR 1998-15398		19981002
EE 200000199	A	20010416	EE 2000-200000199		19981002
JP 2001519331	T2	20011023	JP 2000-514886		19981002
TW 541304	B	20030711	TW 1998-87116499		19981021
NO 2000000783	A	20000529	NO 2000-783		20000217
PRIORITY APPLN. INFO.:			US 1997-62418P	P	19971003
			WO 1998-US21037	W	19981002

OTHER SOURCE(S): MARPAT 130:296611
GI

h eb c g cg b cg eb



I



II

AB Title compds. [I; A is selected from COOH, CH2COOH, CONHOH, SH, CH2SH, PO(OH)2, etc.; ring B is a 4-8 membered cyclic amide contg. 0-3 heteroatoms from O, N, and S, etc.; R1 is phenylmethoxyphenyl, phenoxyphenyl, etc.; R2 is H, CH3, Et, i-Pr, etc.; R1-R2 combine to form heterocyclic; R3 is H, alkylene, heterocyclic, etc.; R4 is H, alkylene, etc.; R3-R4 combine to form heterocyclic], stereoisomer, and pharmaceutically acceptable salt thereof are prepd. as useful metalloprotease inhibitors. Thus, compd. II was prepd. via alkylation, oxidn., amination, and cyclization.

IT **223403-20-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel lactam metalloprotease inhibitors)

RN 223403-20-1 HCAPLUS

CN 1-Pyrrolidineacetamide, 3-[4-[(2,6-dichloro-4-pyridinyl)methoxy]phenyl]-N-hydroxy-α-methyl-2-oxo-3-[[(4-pyridinylamino)carbonyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:38:42 ON 26 AUG 2004)

h eb c g cg b cg eb

```
     FILE 'REGISTRY' ENTERED AT 15:38:49 ON 26 AUG 2004
L1              STRUCTURE UPLOADED
L2            8 S L1
L3          813 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 15:50:21 ON 26 AUG 2004
L4           28 S L3
L5            3 S L4 AND LU, Z?/AU
L6           25 S L4 NOT L5
L7            4 S L6 AND MADUSKUIE, T?/AU

=> s l6 not l7
L8           21 L6 NOT L7

=> s l8 and voss, m?/au
           193 VOSS, M?/AU
L9           0 L8 AND VOSS, M?/AU

=> s l8 and xue, c?/au
           590 XUE, C?/AU
L10          1 L8 AND XUE, C?/AU

=> d l10, ibib abs fhitstr, 1

L10  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

Full Text | Other References

ACCESSION NUMBER: 2002:927249 HCAPLUS
DOCUMENT NUMBER: 138:14059
TITLE: Preparation of spiro-fused hydantoin derivatives as inhibitors of matrix metalloproteinases
INVENTOR(S): Sheppeck, James E.; Duan, Jingwu; **Xue, Chu-Biao**; Wasserman, Zelda
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 350 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096426	A1	20021205	WO 2002-US16381	20020523
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003130273	A1	20030710	US 2002-155575	20020523
EP 1397137	A1	20040317	EP 2002-741724	20020523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:			
	US 2001-293571P	P	20010525
	WO 2002-US16381	W	20020523

h eb c g cg b cg eb

OTHER SOURCE(S): MARPAT 138:14059
GI



I



II

AB Title compds. I [R11 = W-U-X-Y-Z-Ua-Xa-Ya-Za; W = alkyl, alkenylene, alkynylene; U = absent, amino, CO, alkyl, carboxy, etc.; X = absent, alk(en/yn)ylene; Y = absent, O, amino, SO0-2, CO; Z = (hetero)cycle; Ua = absent, O, amino, CO, alkyl, carboxy, etc.; Xa = absent, alk(en/yn)ylene; Ya = absent, O, amino, SO0-2, CO; Za = (hetero)cycle; R1-2 together with the carbon atoms to which they are attached, combine to form a 3-8 membered carbocyclic or heterocyclic ring; R3 = H, CHF2, CH2F, CF3, alk(en/yn)ylene, etc.; R4-7 = H, alk(en/yn)yl; n = 0-1] were prepd. For instance, 2-(ethylcarboxy)cyclohexanone was treated with ammonium carbonate and potassium cyanide (EtOHaq, 50°, 24 h) to afford the corresponding hydantoin ester which was hydrolyzed to the carboxylic acid and coupled to 4-[(2-methyl-4-quinolinyl)methoxy]aniline•2HCl (DMSO, PyBOP) to give II which was isolated as the trifluoroacetate. I are useful as inhibitors of matrix metallproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.

IT **477584-63-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(hydantion derivs. as inhibitors of matrix metalloproteinases)

RN 477584-63-7 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

h eb c g cg b cg eb

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 15:38:42 ON 26 AUG 2004)

     FILE 'REGISTRY' ENTERED AT 15:38:49 ON 26 AUG 2004
L1               STRUCTURE UPLOADED
L2             8 S L1
L3           813 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 15:50:21 ON 26 AUG 2004
L4            28 S L3
L5             3 S L4 AND LU, Z?/AU
L6            25 S L4 NOT L5
L7             4 S L6 AND MADUSKUIE, T?/AU
L8            21 S L6 NOT L7
L9             0 S L8 AND VOSS, M?/AU
L10            1 S L8 AND XUE, C?/AU

=> s l8 not l10
L11           20 L8 NOT L10

=> s l11 and duan, j?/au
            732 DUAN, J?/AU
L12           2 L11 AND DUAN, J?/AU

=> d l12, ibib abs fhitstr, 1-2

L12  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

h eb c g cg b cg eb

Full Text | Citing References

ACCESSION NUMBER: 2004:292661 HCAPLUS
DOCUMENT NUMBER: 141:17257
TITLE: Inhibition of tumor necrosis factor-α-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats
AUTHOR(S): Wang, Xinkang; Feuerstein, Giora Z.; Xu, Lin; Wang, Hugh; Schumacher, William A.; Ogletree, Martin L.; Taub, Rebecca; **Duan, James J.-W.**; Decicco, Carl P.; Liu, Rui-Qin
CORPORATE SOURCE: Department of Thrombosis Research, Bristol-Myers Squibb Company, Princeton, NJ, 08543-5400, USA
SOURCE: Molecular Pharmacology (2004), 65(4), 890-896
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Tumor necrosis factor α (TNFα) is an immunomodulatory and proinflammatory cytokine implicated in neuroinflammation and neuronal damage in response to cerebral ischemia. Tumor necrosis factor-α converting enzyme (TACE or ADAM17) is a key sheddase that releases TNFα from its inactive cell-bound precursor. Using a selective small mol. inhibitor of TACE, DPH-067517, we tested the hypothesis that inhibition of TNFα formation might have a salutary effect in ischemic stroke induced by embolic occlusion of the middle cerebral artery (MCAO). DPH-067517 selectively inhibited TACE enzyme activity in vitro (Ki = 2.8 nM), and effectively suppressed ischemia-induced increase in sol. TNFα in brain tissue after systemic administration. DPH-067517 (3 and 30 mg/kg, i.p. administered 15 min before MCAO) produced 43% (n = 8, p = 0.16) and 58% (n = 8, p < 0.05) redn. in infarct size and 36% (p < 0.05) and 23% (p < 0.05) redn. in neurol. deficits, resp. The salutary effect of DPH-067517 in ischemic brain injury was also obsd. when the first dose was administered 60 min after the onset of ischemia. Inhibition of TACE had no effect on apoptosis measured by levels of active caspase-3 expression and DNA fragmentation. Our data suggest that inhibition of TACE might be a potential therapeutic strategy for neuroprotection after focal ischemic stroke.

IT **362698-30-4**, DPH 067517
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of tumor necrosis factor-α-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats)

RN 362698-30-4 HCAPLUS
CN 4-Piperidineacetamide, N-hydroxy-2,6-dimethyl-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, (2α,4β,6α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:950052 HCAPLUS
DOCUMENT NUMBER: 140:13040
TITLE: Combined use of TACE inhibitors and COX2 inhibitors as anti-inflammatory agents
INVENTOR(S): **Duan, Jingwu**
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003225054	A1	20031204	US 2003-453036		20030603
PRIORITY APPLN. INFO.:			US 2002-385656P	P	20020603

OTHER SOURCE(S): MARPAT 140:13040

AB This invention relates to a method of treating inflammatory diseases in a mammal comprising administering to the mammal a therapeutically effective amt. of a combination of: (i) at least one TACE inhibitor, (ii) one or more anti-inflammatory agents selected from the group consisting of: selective COX-2 inhibitors, interleukin-1 antagonists, dihydroorotate synthase inhibitors, p38 MAP kinase inhibitors, TNF-α inhibitors, TNF-α sequestration agents, and methotrexate. The invention also relates to compns. and kits contg. the same.

IT **362485-76-5**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined use of TACE inhibitors and COX2 inhibitors as anti-inflammatory agents)

RN 362485-76-5 HCAPLUS
CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

h eb c g cg b cg eb

PAGE 1-A



PAGE 2-A




```
=> d his

     (FILE 'HOME' ENTERED AT 15:38:42 ON 26 AUG 2004)

     FILE 'REGISTRY' ENTERED AT 15:38:49 ON 26 AUG 2004
L1               STRUCTURE UPLOADED
L2             8 S L1
L3           813 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 15:50:21 ON 26 AUG 2004
L4            28 S L3
L5             3 S L4 AND LU, Z?/AU
L6            25 S L4 NOT L5
L7             4 S L6 AND MADUSKUIE, T?/AU
L8            21 S L6 NOT L7
L9             0 S L8 AND VOSS, M?/AU
L10            1 S L8 AND XUE, C?/AU
L11           20 S L8 NOT L10
L12            2 S L11 AND DUAN, J?/AU

=> s l11 not l12
L13           18 L11 NOT L12

=> s l13 and ott, g?/au
            333 OTT, G?/AU
```

h eb c g cg b cg eb

```
L14           0 L13 AND OTT, G?/AU

=> s l13 and chen, l?/au
         14342 CHEN, L?/AU
L15           0 L13 AND CHEN, L?/AU

=> s l13 and decicco, c?/au
           130 DECICCO, C?/AU
L16           0 L13 AND DECICCO, C?/AU

=> d l13, ibib abs fhitstr, 1-18

L13  ANSWER 1 OF 18  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

Full Text | Other References

ACCESSION NUMBER: 2004:512993 HCAPLUS
DOCUMENT NUMBER: 141:76809
TITLE: Anti-inflammatory coatings for implantable medical devices containing a TACE inhibitor
INVENTOR(S): Dodd, John H.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004120977	A1	20040624	US 2003-732570		20031210
PRIORITY APPLN. INFO.:			US 2002-434007P	P	20021217
			US 2003-482273P	P	20030625

AB The present invention relates to implantable surgical medical devices having coatings comprising one or more compds. that inhibit TNF-α converting enzyme (TACE), more particularly, stents having coatings comprising TACE inhibitors. A TACE inhibitor is effective in reducing restenosis.

IT **362485-76-5**
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory coatings for implantable medical devices contg. TACE inhibitor)
RN 362485-76-5 HCAPLUS
CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L13 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:331915 HCAPLUS
DOCUMENT NUMBER: 140:357353
TITLE: Preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents
INVENTOR(S): King, Bryan W.; Sheppeck, James; Gilmore, John L.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032846	A2	20040422	WO 2003-US31537	20031003
WO 2004032846	A3	20040715		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

h eb c g cg b cg eb

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ,
BY, KG, KZ, MD
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

US 2004116491 A1 20040617 US 2003-678331 20031003
PRIORITY APPLN. INFO.: US 2002-416709P P 20021007
OTHER SOURCE(S): MARPAT 140:357353
GI



AB The present application describes novel hydantoin derivs. (shown as I; A = O, S; L-R11 represents a very large variety of substituents and is defined in the claims; e.g. II) or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof. Some examples of I exhibit Ki's <10 μM but individual data are not presented. Although the methods of prepn. are not claimed, 37 example prepns. are included. For example, II was prepd. in 4 steps (100, 66, 73 and 82%, resp.) starting with condensation of Et 4-aminobutyrate hydrochloride with 4-(2-methylquinolin-4-ylmethoxy)benzoyl chloride hydrochloride followed by base hydrolysis to the acid, followed by hydrazide formation with thiosemicarbazide followed by cyclization.

IT **681283-94-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

RN 681283-94-3 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(2,5-dihydro-5-thioxo-1H-1,2,4-triazol-3-yl)methyl]-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

h eb c g cg b cg eb

PAGE 1-A



PAGE 2-A



L13 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:291088 HCAPLUS
DOCUMENT NUMBER: 140:321350
TITLE: Preparation of indazolecarboxamides as CDK1, CDK2, and CDK4 inhibitors for treating CDK-related diseases, in particular cancer
INVENTOR(S): D'Orchymont, Hugues; Van Hijfte, Luc; Zimmermann, Andre
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.
SOURCE: Fr. Demande, 90 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2845382	A1	20040409	FR 2002-12188	20021002
WO 2004031158	A1	20040415	WO 2003-FR2862	20030930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,

h eb c g cg b cg eb

NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: FR 2002-12188 A 20021002

OTHER SOURCE(S): MARPAT 140:321350

GI



I



II

AB Title compds. I [R1 = H, halo, NH2, NHR2, NHCOR2, NO2, CN, CH2NH2, CH2NHR2, (un)substituted Ph, heteroaryl; Ar = (un)substituted Ph, heteroaryl; R2 = Ph, heteroaryl, (un)substituted alkyl (substitutent = Ph or heteroaryl); n = 0, 1, 2, or 3; PG = protecting group selected from trimethylsilylethoxymethyl, mesitylenesulfonyl; their free bases, addn. salts with acids, solvates and hydrates; with the exclusion of certain compds.] were prepd. as cyclin-dependent kinase (CDK)-1, CDK2, and CDK4 inhibitors for treating cdk-related diseases, in particular cancer. For instance, reacting indazole-3-carboxylic acid with N-phenyl-1,4-phenylenediamine in the presence of DCC gave 58% II. I displayed IC50 values < 20 μM for the inhibition of CDK2, CDK1, and CDK4 in a test for measuring the enzymic activity of CDK2/Cyclin A, CDK1/Cyclin B, and CDK4/Cyclin D1, resp. I are useful for treating cancers, autoimmune diseases, inflammations, cardiovascular diseases, viral and fungal infections, hematol. diseases, and degenerative diseases of muscular system.

IT **677702-10-2P**, N-(Pyridin-4-yl)-5-[4-methyl-5-(phenoxymethyl)pyridin-3-yl]-1H-indazole-3-carboxamide hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor agent; prepn. of indazolecarboxamides as cdk1, cdk2, and cdk4 inhibitors)

RN 677702-10-2 HCAPLUS

CN 1H-Indazole-3-carboxamide, 5-[4-methyl-5-(phenoxymethyl)-3-pyridinyl]-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:931365 HCAPLUS
DOCUMENT NUMBER: 140:5078
TITLE: Preparation of dipyridodiazepine non-nucleoside reverse transcriptase inhibitors
INVENTOR(S): Simoneau, Bruno; Landry, Serge; Malenfant, Eric; Naud, Julie; O'meara, Jeffrey; Thavonekham, Bounkham; Yoakim, Christiane
PATENT ASSIGNEE(S): Boehringer Ingelheim International Gmbh, Germany
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097644	A2	20031127	WO 2003-CA718	20030514
WO 2003097644	A3	20040205		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004006071	A1	20040108	US 2003-430116	20030506
PRIORITY APPLN. INFO.:			US 2002-380886P	P 20020516

OTHER SOURCE(S): MARPAT 140:5078
GI



I



II

AB The title compds. [I; R2 = H, alkyl, halo, haloalkyl, OH, alkoxy, NH(alkyl) or N(alkyl)2; R4 = H, Me; R5 = H, Me; R11 = H, alkyl, cycloalkyl and alkylcycloalkyl; A = alkylene; B = O, S; n = 0-1; when n = 0, Ring C = (un)substituted 6-10 membered aryl, 5-6 membered heterocycle having from 1-4 heteroatoms selected from O, N, and S; E = CONR12R13 (R12, R13 = H, SO2alkyl, alkylCO2H, alkylcycloalkyl), CONHNR14R15 (R14, R15 = H, alkyl optionally substituted by CO2H), NR16COR17 (R16 = H, alkyl optionally substituted with CO2H, arylCO2H; R17 = alkenylCO2H, cycloalkylCO2H, NHalkylCO2H, etc.), NR18SO2alkyl (R18 = H, alkyl), SO2NR19R20 (R19 = H, alkyl; R20 = alkyl optionally substituted with CO2H), SO2R21 (R21 = alkyl); or when n = 1, Ring C is as defined above and E = a single bond or a connecting group; Ring D = (un)substituted 6-10 membered aryl, 5-6 membered heterocycle having from 1-4 heteroatoms selected from O, N, and S] or a salts or a prodrugs thereof, useful as inhibitors of HIV reverse transcriptase, were prepd. Thus, reacting 11-ethyl-5,11-dihydro-8-(2-hydroxyethyl)-5-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one with Me 4'-hydroxy-3'-methyl-[1,1'-biphenyl]-4-carboxylate (prepn. given) in the presence of DEAD, PPh3 in THF followed by hydrolysis of the resulting ester afforded II which showed IC50 of <10 nM in wild type RT assay. Pharmaceutical compn. for the treatment or prevention of HIV infection, comprising the compd. I is claimed.

IT **627905-95-7P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of dipyridodiazepine non-nucleoside reverse transcriptase inhibitors)

RN 627905-95-7 HCAPLUS

CN Benzamide, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3-methyl-N-(1-oxido-4-pyridinyl)-(9CI) (CA INDEX NAME)

h eb c g cg b cg eb



L13 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:532638 HCAPLUS
DOCUMENT NUMBER: 139:101146
TITLE: Preparation of benzyl or heterocyclylmethyl phenyl or heterocyclyl sulfones as β-amyloid protein production/secretion inhibitors
INVENTOR(S): Yasukochi, Takanori; Ito, Masayuki; Kubota, Hideki; Miyauchi, Satoshi; Saito, Masaki
PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 540 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055850	A1	20030710	WO 2002-JP13792	20021227

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2001-395701 A 20011227
OTHER SOURCE(S): MARPAT 139:101146

AB Novel compds. having various substituents as represented by the following general formula R1(R2)(R3)C-X-R4, salts thereof, and solvates of the same [wherein X = S, SO, SO2; R1 = CR5R6R7, NR8R9, X1R10, X2R11; wherein R5, R6, R7 = halo, cyano, NO2, -Q51-Q52-Q53-Q54; Q51, Q53 = single bond, CO, S(O), SO2, COCO, COC(S), C(S)C(S); Q52 = single bond, O, ON(A51), ON(COA51), N(A51), N(COA51), N(CO2A51), N[CON(A51)(A52)], N(OA51), N(NA51A52), N(A51)N(A52), N(COA51)N(A52), N(A51)-O, N(COA51)-O, S, N:N, C(A51):N, C(A51):N-O, C(A51):N-N(A52), N:C(A51), O-N:C(A51), N(A51)-N:C(A52), C(:NA51)-N(A52); Q54 = A53, OA53, N(A53)(A54), SA53, NA54-OA53, NA55-N(A53)(A54), O-N(A53)(A54); wherein A51, A52, A53 = H, (un)substituted hydrocarbyl or heterocyclyl; R2, R3, R4, R8, R9, R10, R11 = -Q51-Q52-Q53-Q54 defined in R5-R7; X1 = O, S; X2 = SO, SO2; or R1 and R2 or R3 and R4 are combined together to form (un)substituted cyclohydrocarbyl or heterocyclyl] are prepd. These compds. have an effect of inhibiting the prodn./secretion of a β-amyloid protein and are useful for the prevention or treatment of diseases caused by unusual

h eb c g cg b cg eb

prodn./secretion of β-amyloid, in particular Alzheimer's disease or Down's syndrome. Thus, a soln. of 100 mg 2,5-dichloro-4-[(4-chlorophenylthio)-(2,5-difluorophenyl)methyl]pyridine (prepn. given) and 200 μL morpholine in 1.0 mL 1,4-dioxane was stirred at 100° for 2 days to give 4-[5-chloro-4-[(4-chlorophenylthio)-(2,5-difluorophenyl)methyl]pyridin-2-yl]morpholine which (90 mg) was dissolved in 12 mL MeOH, treated with 60 mg ammonium molybdate tetrahydrate [(NH4)6Mo7O24.4H2O] and 6 mL 30% H2O2, and stirred for 8 h to give 83% 4-[5-chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]pyridin-2-yl]morpholine (I). I in vitro glioma cell (H4 cell) expressing human β-amyloid protein precursor protein gene (APP751 gene) with EC50 of ≤50 nM.

IT **558465-17-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzyl or heterocyclylmethyl Ph or heterocyclyl sulfones as β-amyloid protein prodn./secretion inhibitors for treatment or prepn. of Alzheimer's disease or Down's syndrome)

RN 558465-17-1 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl)methyl]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:5785 HCAPLUS
DOCUMENT NUMBER: 138:73180
TITLE: Preparation of amino-nicotinate derivatives for therapeutic use as glucokinase (GLK) modulators
INVENTOR(S): Hayter, Barry Raymond; Currie, Gordon Stuart; Hargreaves, Rodney Brian; James, Roger; Jones, Clifford David; Mckerrecher, Darren; Allen, Joanne Victoria; Caulkett, Peter William Rodney; Johnstone, Craig; Gaskin, Harold
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000267	A1	20030103	WO 2002-GB2873	20020624

h eb c g cg b cg eb

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1404335 A1 20040407 EP 2002-740900 20020624

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2002010711 A 20040720 BR 2002-10711 20020624

PRIORITY APPLN. INFO.: SE 2001-2300 A 20010626

WO 2002-GB2873 W 20020624

OTHER SOURCE(S): MARPAT 138:73180

GI



AB Aminonicotinates, such as I [R1 = H, OH, (CH2)1-4OH, NO2, NH2, haloalkyl, haloalkyloxy, alkyl, alkenyl, alkylamino, etc.; R2 = X-Y; X = linking group, such as O, CO, amino, Z-O-Z, etc; Z = alkylene, alkenylene, etc.; R3 = OH, alkoxy, alkylamino, etc.; m = 0-2; n = 0-4; m + n > 0], were prepd. for pharmaceutical use in the treatment of diseases or conditions mediated through glucokinase (GLK), such as type 2 diabetes. Thus, nicotinic acid deriv. II (R3 = OH) was prepd. by treatment of 3,5-dibenzyloxybenzoic acid with oxalyl chloride in CH2Cl2 and DMF followed by addn. of Me 6-aminonicotinate to the reaction mixt. form ester II (R3 = OMe) in 57% yield and subsequent hydrolysis of the ester using LiOH in THF/H2O to give the desired acid in 17% yield. The prepd. compds. were assayed for their effect on GLK activity, and pharmaceutical compns. of the prepd. compds. were presented.

IT **480463-03-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of amino nicotinate derivs. for therapeutic use as glucokinase (GLK) modulators)

RN 480463-03-4 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[3-(1-methylethoxy)-5-(2-pyridinylmethoxy)benzoyl]amino]- (9CI) (CA INDEX NAME)

h eb c g cg b cg eb



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:754333 HCAPLUS
DOCUMENT NUMBER: 137:279214
TITLE: Preparation of benzoic acid derivatives as nuclear factor κB inhibitors
INVENTOR(S): Suzuki, Kenji; Nunokawa, Youichi; Ogou, Naohisa
PATENT ASSIGNEE(S): Suntory Limited, Japan; Suntory Biomedical Research Limited
SOURCE: PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002076918	A1	20021003	WO 2002-JP3017		20020327
WO 2002076918	C1	20021031			
W: BR, CA, CN, HU, JP, KR, US					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR					
BR 2002004678	A	20030429	BR 2002-4678		20020327
EP 1314712	A1	20030528	EP 2002-708696		20020327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
US 2004122244	A1	20040624	US 2002-296810		20021127
PRIORITY APPLN. INFO.:			JP 2001-91003	A	20010327
			WO 2002-JP3017	W	20020327

OTHER SOURCE(S): MARPAT 137:279214
GI



I

AB The title compds. I [R1 = (1,4-benzoquinon-2-yl)methyl (with substituents selected from H, alkyl, etc.) (generic structure given), etc.; R2 = H, (un)substituted alkyl, etc.; X = carboxyl (which may esterified or amidated)] are prepd. In an in vitro test for nuclear factor κB inhibiting activity, N-[5-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-yl)methyl-2-hydroxybenzoyl]-4-aminobenzoic acid Et ester showed IC50 value of 3 μg/mL.

IT **464215-26-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

h eb c g cg b cg eb

(Uses)
(prepn. of benzoic acid derivs. as nuclear factor κB inhibitors)
RN 464215-26-7 HCAPLUS
CN Benzamide, 5-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-4-pyridinyl-2-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:591913 HCAPLUS
DOCUMENT NUMBER: 137:150215
TITLE: Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents
INVENTOR(S): Hatayama, Satoshi; Hayashi, Kyoko; Honma, Mitsuki; Takahashi, Ikuko
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 194 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002220338	A2	20020809	JP 2001-18755	20010126
PRIORITY APPLN. INFO.:			JP 2001-18755	20010126

OTHER SOURCE(S): MARPAT 137:150215
GI

h eb c g cg b cg eb



I

AB This invention relates to the general structures (I; Ar = N-contg. hetero arom. ring, X, Z = C, etc.; Y = CO, etc.; R1-R5 = H, etc.) and their salts as Cdk4 and/or Cdk6 inhibitors. I have antiproliferative effects on cancer cells and are potential antitumor agents. Formulation examples of I capsules, tablets, and injections were given.

IT **322686-55-5**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents)

RN 322686-55-5 HCAPLUS

CN Urea, N-[4-[2-[[[4-(3-pyridinylmethoxy)phenyl]methyl]amino]ethyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



L13 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER:	2001:886851 HCAPLUS
DOCUMENT NUMBER:	136:20023
TITLE:	Preparation of pyridine-substituted benzanilides as potassium channel openers
INVENTOR(S):	McNaughton-Smith, Grant; Fritch, Paul Christopher; Amato, George Salvatore
PATENT ASSIGNEE(S):	USA
SOURCE:	U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 632,576. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

h eb c g cg b cg eb

09/939230

US 2001049444	A1	20011206	US 2001-776791	20010202
US 6495550	B2	20021217		
US 6326385	B1	20011204	US 2000-631747	20000804
US 6372767	B1	20020416	US 2000-632576	20000804
US 2002013349	A1	20020131	US 2001-939230	20010824
US 2002091122	A1	20020711	US 2001-4122	20011101
US 6737422	B2	20040518		
US 2002052393	A1	20020502	US 2001-2800	20011102
US 6605725	B2	20030812		
WO 2002062295	A2	20020815	WO 2002-US3061	20020201
WO 2002062295	A3	20030703		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1363884	A2	20031126	EP 2002-704333	20020201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

US 1999-147221P	P	19990804
US 2000-632576	A2	20000804
US 1999-158712P	P	19991008
US 1999-165847P	P	19991116
US 2000-631747	A	20000804
US 2001-776791	A	20010202
WO 2002-US3061	W	20020201

OTHER SOURCE(S): MARPAT 136:20023

GI



I

AB The title compds. [I; Y = H, Me, OMe, OCF3, halo; V, X = H, halo, alkyl, etc.; R1 = alkyl, heteroalkyl, aryl, etc.; Q, W = C≡C, (un)substituted CH:CH, alkylene; Z = O, CO, (un)substituted NH, etc.] which are voltage-dependent potassium channel openers, and are useful for the treatment of central and peripheral nervous system disorders, were prepd. General procedures for prepg. compds. I such as 3,4-dichloro-N-(pyridin-3-yl)benzamide were given. The activity of compds. I, assayed according to a KCNQ2 screening protocol, ranged from about 30% to greater than about 70% efflux.

IT **378241-17-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzanilides as potassium channel openers)

RN 378241-17-9 HCAPLUS

h eb c g cg b cg eb

CN Benzamide, N-(6-chloro-3-pyridinyl)-3-fluoro-4-[[2-(2-pyridinyl)ethyl]thio]- (9CI) (CA INDEX NAME)



L13 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:78363 HCAPLUS
DOCUMENT NUMBER: 134:147614
TITLE: Preparation of N,N'-biarylurea derivatives as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6)
INVENTOR(S): Hayama, Takashi; Hayashi, Kyoko; Honma, Mitsutaka; Takahashi, Ikuko
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 460 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007411	A1	20010201	WO 2000-JP4991	20000726
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001106673	A2	20010417	JP 2000-274175	20000726
EP 1199306	A1	20020424	EP 2000-949909	20000726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-211384 A 19990726
WO 2000-JP4991 W 20000726

OTHER SOURCE(S): MARPAT 134:147614
GI



I



II

AB N-(hetero)aryl-N'-heterocyclylurea derivs. represented by general formula (I) [wherein Ar represents a nitrogenous heterocyclic arom. group such as (un)substituted pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, imidazolyl, indolyl, isoindolyl, quinolyl, isoquinolyl, benzothiazolyl, or benzoxazolyl; X and Z each represents C or N or together with R1 or R2 and/or R3 represent CH or N; Y represents CO, SO, or SO2; R1 represents hydrogen, (un)substituted lower alkyl, Y3-W2-Y4-R5, etc.; wherein R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, imidazolyl, isoxazolyl, isoquinolyl, isoindolyl, indazolyl, indolyl, indolidinyl, isothiazolyl, ethylenedioxyphenyl, oxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, quinoxalinyl, quinolyl, etc.; W2 = ingle bond, O, S, SO, SO2, N-(un)substituted NH, SO2NH, NHSO2NH, NHSO2, CONH, NHCO, NHCONH, NHCO2, etc.; Y3, Y4 = single bond, linear or branched lower alkylene; R2 and R3 each represents hydrogen, lower alkyl or alkoxy, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above), or one of R2 and R3 together with R1 and X forms cyclohexane, cyclopentane, piperidine, 3,4,5,6-tetrahydro-1,3-oxazine, tetrahydrothiopyran, pyrrolidine, tetrahydrothiofuran, oxazolidine ring, etc.; R4 and R5 represent H, halo, OH, amino, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above)] or salts thereof are prepd. The compds. (e.g. II) have a remarkable proliferation-inhibitory effect on tumor cells. A Cdk4 and/or Cdk6 inhibitor for use in the therapy of malignant tumor can hence be provided. II showed IC50 of 0.061 and 0.019 μM against cyclin-D1-Cdk4 and cyclin-D2-Cdk4, resp., vs. 0.36 and 0.056 μM, resp., for (±)-flavopiridol, and inhibited the proliferation of HCT116 and MKN-1 cells with IC50 of 0.013 and 0.10 μM, resp., vs. 0.15 and 0.87 μM, resp., for (±)-flavopiridol. Pharmaceutical formulations contg. I were prepd.

IT **322686-59-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(hetero)aryl-N'-heterocyclylurea derivs. as in inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)

RN 322686-59-9 HCAPLUS

CN Urea, N-[4-[2-[[[4-(4-pyridinylmethoxy)phenyl]methyl]amino]ethyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

h eb c g cg b cg eb



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:566030 HCAPLUS
DOCUMENT NUMBER: 131:170353
TITLE: Method for preparation of pyridone urea derivatives from amino or carbamoylpyridone derivatives
INVENTOR(S): Muraoka, Masami; Morishita, Koji; Aida, Nagisa; Tanaka, Masashi; Yuri, Masatoshi; Ohashi, Naohito
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943659	A1	19990902	WO 1999-JP718	19990217
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2321237	AA	19990902	CA 1999-2321237	19990217
AU 9925473	A1	19990915	AU 1999-25473	19990217
EP 1086948	A1	20010328	EP 1999-905228	19990217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
US 6300500	B1	20011009	US 2000-623030	20000825
US 2001051732	A1	20011213	US 2001-853953	20010514
US 6452008	B2	20020917		

PRIORITY APPLN. INFO.:		
JP 1998-62346	A	19980225
JP 1998-92567	A	19980319
WO 1999-JP718	W	19990217
US 2000-623030	A3	20000825

OTHER SOURCE(S): CASREACT 131:170353; MARPAT 131:170353
GI

h eb c g cg b cg eb



I



II

AB A process for producing a pyridone deriv. represented by general formula [I; R = NHCONH-L; R1 = H, (un)substituted alkyl, alkenyl, alkynyl, or cycloalkyl; Y1 = H, (un)substituted alkyl, cycloalkyl, or arom. group; Y2, Y3 = H, halo, OH, cyano, CF3, NO2, NH2 mono- or dialkylamino, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, (un)substituted alkyl, cycloalkyl, or arom. group; or Y2 and Y3 are linked together to form an (un)substituted pyridine] is characterized by reacting (oxidizing) a carbamoylpyridone represented by general formula I (R = CONH2) with a hypochlorite or hypobromite or with lead tetraacetate to give isocyanatopyridone represented by general formula I(R = isocyanato) and reacting this compd. with an amine represented by general formula L-NH2. The process is preferable, esp. from the standpoint of safety. The N-(2-oxo-1,2-dihydropyridyl)urea derivs. possess acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory-activity and are useful for the treatment of hyperlipidemia and arteriosclerosis (no data). Thus, 14.5 g lead tetraacetate was added to a suspension of 10.0 g 1-butyl-3-carbamoyl-4-(3-methoxyphenyl)-1,2-dihydro-2-oxo-1,8-naphthyridine in 100 mL DMF and stirred at room temp. for 0.5 h, followed by adding 5.3 g 2,6-diisopropylaniline at room temp., and the resulting mixt. was stirred at 40-50° for 1.5 h to give 68% N-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-N'-phenylurea (II).

IT **239098-59-0P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(dihydrooxopyridyl)urea derivs. from amino or carbamoylpyridone derivs.)

RN 239098-59-0 HCAPLUS

CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-butyl-1,2-dihydro-2-oxo-4-[3-(3-pyridinylmethoxy)phenyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:464280 HCAPLUS

DOCUMENT NUMBER: 131:116153

h eb c g cg b cg eb

TITLE: Preparation of N-(phenylcyclopropyl)-N'-pyridylurea derivatives as antivirals and as HIV reverse transcriptase inhibitors

INVENTOR(S): Sahlberg, Christer; Noreen, Rolf; Hogberg, Marita; Engelhardt, Per

PATENT ASSIGNEE(S): Medivir AB, Swed.

SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9936406	A1	19990722	WO 1999-SE53	19990115
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9900292	A	19990715	ZA 1999-292	19990115
CA 2318694	AA	19990722	CA 1999-2318694	19990115
AU 9924450	A1	19990802	AU 1999-24450	19990115
AU 739766	B2	20011018		
EP 1054867	A1	20001129	EP 1999-903983	19990115
EP 1054867	B1	20040414		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200002058	T2	20010521	TR 2000-200002058	19990115
BR 9906933	A	20011127	BR 1999-6933	19990115
TW 470645	B	20020101	TW 1999-88100605	19990115
JP 2002509137	T2	20020326	JP 2000-540122	19990115
NZ 505543	A	20020927	NZ 1999-505543	19990115
AT 264305	E	20040415	AT 1999-903983	19990115
US 6486183	B1	20021126	US 2000-600309	20001113
US 2003119881	A1	20030626	US 2002-243118	20020912

PRIORITY APPLN. INFO.:

SE 1998-113	A	19980116
SE 1998-116	A	19980116
WO 1999-SE53	W	19990115
US 2000-600309	A3	20001113

OTHER SOURCE(S): MARPAT 131:116153

GI



I

AB The title compds. I (Rx = cyano, Br; R1 = halo; R2 = C1-C3 alkyl), antiretrovirals with HIV reverse transcriptase inhibiting activity, were prepd. E.g., (1S,2S)-N-[cis-2-(6-fluoro-2-hydroxy-3-propionylphenyl)cyclopropyl]-N'-(5-cyanopyrid-2-yl)urea was prepd.

h eb c g cg b cg eb

IT **231957-60-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(phenylcyclopropyl)-N'-pyridylurea derivs. as antivirals and as HIV reverse transcriptase inhibitors)
RN 231957-60-1 HCAPLUS
CN 4-Pyridinecarboxylic acid, 2-[(1S,2S)-2-[[[(5-bromo-2-pyridinyl)amino]carbonyl]amino]cyclopropyl]-3-fluoro-6-(1-oxopropyl)phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | More References

ACCESSION NUMBER: 1997:218623 HCAPLUS
DOCUMENT NUMBER: 126:212048
TITLE: Substituted aromatic compounds and their pharmaceutical use as inhibitors of TNF and PDE IV.
INVENTOR(S): Aldous, David John; Smith, Graham Frank; Astles, Peter Charles; Pickett, Stephen Dennis; McLay, Iain McFarlane; Stuttle, Keith Alfred James; Ratcliffe, Andrew James; et al.
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Limited, UK
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9703967	A1	19970206	WO 1996-GB1746	19960722

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM

h eb c g cg b cg eb

AU 9665268	A1	19970218	AU 1996-65268		19960722
PRIORITY APPLN. INFO.:			GB 1995-15058	A	19950722
			GB 1995-15729	A	19950801
			GB 1996-4531	A	19960302
			US 1996-14212P	P	19960327
			WO 1996-GB1746	W	19960722

OTHER SOURCE(S): MARPAT 126:212048

GI



I



II

AB The invention describes compds. I [wherein R1 = (un)substituted alkyl, or when Z1 = bond, R1 may also = H; R2 = (un)substituted aryl, partially satd. bicycloaryl, heteroaryl, or RaRbN; R3 = (un)substituted aryl or heteroaryl; A1 = bond, (un)substituted C1-6 alkylene or C2-6 alk(en/yn)ylene optionally interrupted by O, S, phenylene, imino, alkylimino, SO, or SO2; Z1, Z2 = O, S or bond; Z3 = C≡C, CH2CZ, CZCH2, CZCZ, CH2NH, CH2O, CH2S, CH2SO, CH2SO2, CF2O, CZNH, NHCH2, OCH2, SCH2, SOCH2, SO2CH2, OCF2, OCZ, NHCZ, N:N, NHSO2, SO2NH, CZCZNH, NHCOO, OCONH, C(:NORc)CH2, C(F):N, CH(F)CH2, or NHCONH; Z = O or S; Ra, Rb = alkyl or arylalkyl; or NRaRb = 4- to 6-membered cyclic amine optionally contg. addnl. O, S, NH, or NRc or substituted with oxo; Rc = alkyl or arylalkyl; Q1, Q2, Q3 = CH, CX1, or N; and X1 = halo] and their N-oxides, prodrugs, pharmaceutically acceptable salts, and solvates (e.g. hydrates). The invention also describes processes for prepg. I, pharmaceutical compns. comprising I, and their use in therapy as inhibitors of TNF and type IV cAMP phosphodiesterase (PDE) (no data). For example, 5-[[(3,5-dichloropyridin-4-yl)imino]fluoromethyl]-2-methoxyphenol (prepn. given) was etherified with 3-(4-chlorophenyl)-5-(hydroxymethyl)-1,2,4-oxadiazole using the Mitsunobu reaction, followed by conversion of the imidoyl fluoride function to an amide using KOSiMe3, and N-oxidn. using m-ClC6H4C(O)OOH, to give title compd. II.

IT **187968-96-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of substituted arom. compds. as inhibitors of TNF and PDE IV)

RN 187968-96-3 HCAPLUS

CN Benzamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-4-methoxy-3-(2-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

h eb c g cg b cg eb



L13 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1996:337928 HCAPLUS
DOCUMENT NUMBER: 125:33487
TITLE: Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
INVENTOR(S): Brooks, Dee W.; Bhatia, Pramila; Kolasa, Teodozyj; Stewart, Andrew O.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9602507	A1	19960201	WO 1995-US8367	19950628
W: AU, CA, JP, KR, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5512581	A	19960430	US 1995-432491	19950501
CA 2191975	AA	19960201	CA 1995-2191975	19950628
AU 9530023	A1	19960216	AU 1995-30023	19950628
EP 772594	A1	19970514	EP 1995-926167	19950628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 2001518050	T2	20011009	JP 1996-505058	19950628
PRIORITY APPLN. INFO.:			US 1994-276148 A	19940718
			WO 1995-US8367 W	19950628

OTHER SOURCE(S): MARPAT 125:33487
GI



I

AB The title compds. WXYCH(R1)ON:C(R2)ACOM [W = (un)substituted aryl or heteroaryl; X = bond, CH2, alkylene, alkenylene, alkynylene, alkenyloxy; Q = bond, O, S, (un)substituted amino, etc.; Y = (un)substituted Ph, biphenyl, naphthyl, tetrahydronaphthyl, indolyl, pyridyl, benzo[b]thienyl, thienyl, thiazolyl, thiazolylphenyl; R1 = alkyl, cycloalkyl, alkoxyalkyl, aryl or arylalkyl, heteroaryl or heteroarylalkyl; R2 = H, alkyl, hydroxyalkyl; A = bond, alkylene, alkenylene, alkynylene, cycloalkylene, phenylene, pyridylene, thienylene, furylene; M = pharmaceutically

h eb c g cg b cg eb

acceptable and metabolically cleavable group, 3-, or 4-pyridyl, 4- or 5-thiazolyl, etc.], which inhibit leukotriene biosynthesis and are useful in the treatment of inflammatory disease states, are prepd. Thus, quinoline deriv. I, prepd. in 5 steps from 4-hydroxybenzaldehyde, demonstrated a IC50 of 0.021 μM against 5-lipoxygenase formation in LTB4-stimulated human polymorphonuclear leukocytes.

IT **177276-04-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(iminoxycarboxylates and derivs. as inhibitors of leukotriene biosynthesis)

RN 177276-04-9 HCAPLUS

CN Propanamide, 2-[[cyclohexyl[4-(2-quinolinylmethoxy)phenyl]methoxy]imino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



L13 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER:	1994:621558 HCAPLUS
DOCUMENT NUMBER:	121:221558
TITLE:	Synthesis of new potent leukotriene B4 antagonists and their biological properties. 2.
AUTHOR(S):	Kawakami, Hajime; Ohmi, Naoko; Nagata, Hideo
CORPORATE SOURCE:	Sumitomo Pharmaceuticals Research Center, Osaka, 554, Japan
SOURCE:	Bioorganic & Medicinal Chemistry Letters (1994), 4(12), 1461-6 CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE:	Journal
LANGUAGE:	English

GI



I

AB The synthesis of new leukotriene B4 antagonists and their biol. properties are described. SM-15178 (I) has potent effects against human neutrophil chemotaxis, and is orally effective against LTB4-induced bronchoconstriction in the guinea pig.

IT **146460-42-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

h eb c g cg b cg eb

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and pharmacol. of leukotriene B4 antagonists)
RN 146460-42-6 HCAPLUS
CN 2-Pyridineacetic acid, 6-[[[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]-2-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



L13 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1993:509007 HCAPLUS
DOCUMENT NUMBER: 119:109007
TITLE: Substituted quinolinyl- and naphthalenylbenzamides or benzylamines and related compounds useful as analgesics
INVENTOR(S): Musser, John H.; Molinari, Albert J.; Mobilio, Dominick
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 18 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5212182	A	19930518	US 1990-592160	19901003
PRIORITY APPLN. INFO.:			US 1990-592160	19901003

OTHER SOURCE(S): MARPAT 119:109007
GI



I

AB The title compds. are I [X = N, NO, CR1; Y = C(R1)(R2)O, OC(R1)(R2), C(R1)(R2)N(R3), N(R3)C(R1)(R2), C(R1):C(R2) (R1-R3 = H, C1-10 alkyl); Z = O, (R1)(R2); R4 = R1, benzyl, Ph, etc.; R5 = R1, C1-10 alkoxy, halo, trihalomethyl, NO2, etc.; R6 = R1 or C(O)(R7) (with proviso that Z is not O) (R7 = R1, Ph, C1-10 perfluoroalkyl, phenylalkyl with 1-10 C in alkyl group)] and pharmaceutically acceptable acid addn. salts thereof. I are used for treatment of bradykinin-mediated pain. Prepn. of a variety of I is described, and the prepd. compds. were tested in a bradykinin receptor assay and for inhibition of bradykinin-induced writhing in mice.
IT **149326-02-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for analgesic)
RN 149326-02-3 HCAPLUS
CN Benzamide, N-[1-(phenylmethyl)-4-piperidinyl]-4-(4-quinolinylmethoxy)-

h eb c g cg b cg eb

(9CI) (CA INDEX NAME)



L13 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | CHAS References

ACCESSION NUMBER:	1993:428148 HCAPLUS
DOCUMENT NUMBER:	119:28148
TITLE:	Preparation of N-heterocyclyl-2-[4-(2-quinolylmethoxy)phenyl]acetamides as lipoxygenase inhibitors
INVENTOR(S):	Raddatz, Siegfried; Mohrs, Klaus Helmut; Matzke, Michael; Fruchtmann, Romanis; Hatzelmann, Armin; Kohlsdorfer, Christian; Mueller-Peddinghaus, Reiner; Theisen-Popp, Pia
PATENT ASSIGNEE(S):	Bayer A.-G., Germany
SOURCE:	Eur. Pat. Appl., 16 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 530639	A1	19930310	EP 1992-114428	19920825
EP 530639	B1	19940817		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 4129742	A1	19930311	DE 1991-4129742	19910906
NO 9203181	A	19930308	NO 1992-3181	19920814
ES 2057953	T3	19941016	ES 1992-114428	19920825
US 5266578	A	19931130	US 1992-936180	19920826

h eb c g cg b cg eb

JP 05194403	A2	19930803	JP 1992-253582	19920831
AU 9222054	A1	19930311	AU 1992-22054	19920901
AU 649351	B2	19940519		
CA 2077465	AA	19930307	CA 1992-2077465	19920903
ZA 9206706	A	19930308	ZA 1992-6706	19920904
HU 65660	A2	19940728	HU 1992-2850	19920904
CN 1070190	A	19930324	CN 1992-110346	19920905

PRIORITY APPLN. INFO.: DE 1991-4129742 19910906
OTHER SOURCE(S): MARPAT 119:28148

AB RCH2OZCHR1CONR2R3 [R = (substituted) 2-quinolyl; R1 = (cyclo)alkyl, aralkyl, etc.; R2 = H, alkyl; R3 = (substituted) heterocyclyl; Z = phenylenediyl] were prepd. Thus, 4-(RCH2O)C6H4CHR1COR4 (R = 2-quinolyl, R1 = cycloheptyl) (I; R4 = OH) was condensed with 2-aminopyridine to give I (R4 = 2-pyridylamino) which had IC50 of 2.6 7-10 ı µM against 5-lipoxygenase in vitro.

IT **148256-28-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as lipoxygenase inhibitor)

RN 148256-28-4 HCAPLUS

CN Cycloheptaneacetamide, N-2-pyridinyl-α-[4-(2-quinolinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1993:169102 HCAPLUS
DOCUMENT NUMBER: 118:169102
TITLE: Preparation of phenoxymethyl(carbamoyl)arenes as leukotriene B4 antagonists
INVENTOR(S): Nagata, Hideo; Kawakami, Hajime
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 147 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 516069	A1	19921202	EP 1992-108916	19920527
EP 516069	B1	19960424		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE				
CA 2069667	AA	19921201	CA 1992-2069667	19920527
AU 9217193	A1	19930311	AU 1992-17193	19920527
AU 643140	B2	19931104		
AT 137223	E	19960515	AT 1992-108916	19920527

h eb c g cg b cg eb

ES 2086579	T3	19960701	ES 1992-108916	19920527
JP 05239004	A2	19930917	JP 1992-164065	19920528
US 5225422	A	19930706	US 1992-891256	19920601
PRIORITY APPLN. INFO.:			JP 1991-157725	19910531

OTHER SOURCE(S): MARPAT 118:169102
GI



I

AB Title compds. I (A = alkylene; B, X = (substituted) phenylene, heteroarylene; Y = bond, O; Z = bond, alkylene; R1 = alkyl; R2 = OH, C1-C5 alkoxy; R3, R4 = H, alkyl, alkenyl or alkynyl; R5 = H, C1-C5 alkyl or hydroxyalkyl; R6 = (modified) carboxy; NR5R6 = heteroarom.) were prepd. as allergy inhibitors and antiinflammatories (no data). Thus, 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxylic acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, 2-aminothiazole-4-carboxamide, and triethylamine were stirred in CH2Cl2/DMF at room temp. for 44 h to give 2-[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxamid]thiazol-4-ylcarboxamide.

IT **148350-76-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidn. of, in prepn. of leukotriene B4 antagonists)

RN 148350-76-9 HCAPLUS
CN 2-Pyridinecarboxylic acid, 6-[[[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]-2-pyridinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.32	329.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-19.60	-19.60

FILE 'CAOLD' ENTERED AT 15:58:28 ON 26 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

h eb c g cg b cg eb

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
=> d his

     (FILE 'HOME' ENTERED AT 15:38:42 ON 26 AUG 2004)

     FILE 'REGISTRY' ENTERED AT 15:38:49 ON 26 AUG 2004
L1             STRUCTURE UPLOADED
L2               8 S L1
L3             813 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 15:50:21 ON 26 AUG 2004
L4              28 S L3
L5               3 S L4 AND LU, Z?/AU
L6              25 S L4 NOT L5
L7               4 S L6 AND MADUSKUIE, T?/AU
L8              21 S L6 NOT L7
L9               0 S L8 AND VOSS, M?/AU
L10              1 S L8 AND XUE, C?/AU
L11             20 S L8 NOT L10
L12              2 S L11 AND DUAN, J?/AU
L13             18 S L11 NOT L12
L14              0 S L13 AND OTT, G?/AU
L15              0 S L13 AND CHEN, L?/AU
L16              0 S L13 AND DECICCO, C?/AU

     FILE 'CAOLD' ENTERED AT 15:58:28 ON 26 AUG 2004

=> s l3
L17              0 L3

=>
```

h eb c g cg b cg eb

C:\stnweb\Queries\3.str



chain nodes :
1 2 4 11 13
ring nodes :
5 6 7 8 9 10 14 15 16 17 18 19 22 23 24 25 26 27
chain bonds :
1-2 2-4 10-11 11-13
ring bonds :
5-6 5-10 6-7 7-8 8-9 9-10 14-15 14-19 15-16 16-17 17-18 18-19 22-23 22-27
23-24 24-25 25-26 26-27
exact/norm bonds :
1-2 2-4 10-11 11-13 22-23 22-27 23-24 24-25 25-26 26-27
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10 14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 5 : 22 :

G1:O,S

Match level :
1:CLASS 2:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:CLASS 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS